Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 12, 2025 • 3:41 PM ET

Date/Time Source News Release
06/12/2025 08:03 AM EDT PR Newswire NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
06/05/2025 08:03 AM EDT PR Newswire NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine
05/21/2025 08:03 AM EDT PR Newswire NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics(TM), Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida
05/15/2025 04:03 PM EDT PR Newswire NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update
05/15/2025 10:15 AM EDT PR Newswire HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions
05/13/2025 08:03 AM EDT PR Newswire HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics
05/12/2025 08:03 AM EDT PR Newswire NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025
05/06/2025 08:03 AM EDT PR Newswire HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025
05/05/2025 08:03 AM EDT PR Newswire NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine
04/30/2025 08:46 AM EDT PR Newswire NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression
Page

Additional News

As of June 12, 2025 • 3:41 PM ET

Date/Time Source News Release
06/12/2025 09:15 AM EDT BioMedWire BioMedNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics to Present at H.C. Wainwright Neuro Perspectives Conference
06/12/2025 09:05 AM EDT PsychedelicNewsWire NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage
06/05/2025 11:20 AM EDT PsychedelicNewsWire NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network
06/05/2025 10:20 AM EDT PsychedelicNewsWire PsychedelicNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine, Targets Expanding $750M Market
05/28/2025 09:50 AM EDT PsychedelicNewsWire NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval
05/23/2025 10:35 AM EDT PsychedelicNewsWire NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition
05/21/2025 09:05 AM EDT BioMedWire BioMedNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Wall Street Conference on May 21
05/20/2025 09:05 AM EDT BioMedWire NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is 'One to Watch'
05/19/2025 02:35 PM EDT PsychedelicNewsWire Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform
05/16/2025 08:46 PM EDT SeekingAlpha NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.